A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: A multicenter clinicopathologic experience and new prognostic score

Cancer

Volumn 116, Issue 14, 2010, Pages 3438-3446

  Phillips, Adrienne A ^a,b   Shapira, Iuliana ^c   Willim, Robert D ^b   Sanmugarajah, Jasotha ^d   Solomon, William B ^e   Horwitz, Steven M ^f   Savage, David G ^a,b   Bhagat, Govind ^a,b   Soff, Gerald ^f   Zain, Jasmine M ^g   Alobeid, Bachir ^a   Seshan, Venkatraman E ^a,b   O'Connor, Owen A ^g  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NewYork Presbyterian Hospital   (United States)

^c HOFSTRA UNIVERSITY   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e Maimonides Cancer Center   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adult T cell leukemia lymphoma; Human T cell lymphotropic virus type 1 (HTLV 1); Non Hodgkin lymphoma; Prognostic factors

Indexed keywords

ALEMTUZUMAB; BEXAROTENE; BORTEZOMIB; CARBOPLATIN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IFOSFAMIDE; INTERFERON; LAMIVUDINE; METHOTREXATE; PRALATREXATE; PREDNISONE; PROCARBAZINE; PSORALEN; VINCRISTINE; ZIDOVUDINE;

ADULT; AGED; AGING; ALLOTRANSPLANTATION; ARTICLE; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL FEATURE; DISEASE COURSE; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; KAPLAN MEIER METHOD; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PUVA; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL MODEL; T CELL LEUKEMIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; PROGNOSIS; UNITED STATES;

EID: 77954947790     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25147     Document Type: Article

References (42)

1. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. A report from the Lymphoma Study Group (1984-1987). Br J Haematol. 1991;79:428-437.
2. Taguchi H, Kinoshita, KI, Takatsuki K, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:182-186.
3. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Study 9303. Br J Haematol. 2001;113:375-382.
4. Shimoyama M. Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Leuk Res. 1991;15:81-90.
5. Takasaki Y, Iwanaga M, Tsukasaki K, et al. Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk Res. 2007;31:751-757.
6. Tsukasaki K, Imaizumi Y, Tawara M. Diversity of leukaemic cell morphology in ATL correlates with prognostic factors, aberrant immunophenotype and defective HTLV-1 genotype. Br J Haematol. 1999;106:369-375.
7. Hisada M, Stuver SO, Okayama A, et al. Persistent paradox of natural history of human T lymphotropic virus type I: parallel analyses of Japanese and Jamaican carriers. J Infect Dis. 2004;190:1605-1609.
8. United States Census Bureau. US Census, 2000. Available at: www.census.gov Accessed March 2008.
9. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
10. Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;55:457-481.
11. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration, Cancer Chemother Rep. 1966;50:163-170.
13. Lausen B, Schumaker M. Maximally selected rank statistics. Biometrics. 1992;48:73-85.
14. Therneau TM, Atkinson EJ. An Introduction to Recursive Partitioning Using the RPART Routine. Technical Report 61. Rochester, Minn: Mayo Clinic, Section of Statistics; 1997.
15. Tajima K. The 4th nation-wide study of adult T-cell leukemia/ lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. Int J Cancer. 1990;45:237-243. (Pubitemid 20061375)
16. Hanchard B. Adult T-cell leukemia/lymphoma in Jamaica: 1986-1995. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(suppl 1):S20-S25.
17. Manns A, Cleghorn FR, Falk RT, et al. Role of HTLV-1 in development of non-Hodgkin lymphoma in Jamaica and Trinidad and Tobago. The HTLV Lymphoma Study Group. Lancet. 1993;342:1447-1450.
18. Deardren C, Corbin D, Prussia P, et al. Clinical and laboratory features of adult T-cell leukaemia lymphoma in Barbados. Leuk Lymphoma. 1996;23:561-565.
19. Catovsky D, Greaves MF, Rose M, et al. Adult T-cell lymphoma-leukaemia in Blacks from the West Indies. Lancet. 1982;1:639-643. (Pubitemid 12179932)
20. Pawson R, Richardson DS, Pagliuca A, et al. Adult T-cell leukemia/lymphoma in London: clinical experience of 21 cases. Leuk Lymphoma. 1998;31:177-185.
21. Levine PH, Cleghorn F, Manns A, et al. Adult T-cell leukemia/ lymphoma: a working point-score classification for epidemiologic studies. Int J Cancer. 1994;59:491-493.
22. Teshima T, Akashi K, Shibuya T, et al. Central nervous system involvement in adult T-cell leukemia/lymphoma. Cancer. 1990;65:327-332.
23. Suzumiya J, Marutsuka K, Nabeshima K, et al. Autopsy findings in 47 cases of adult T-cell leukemia/lymphoma in Miyazaki prefecture, Japan. Leuk Lymphoma. 1993;11:281-286.
24. Yano H, Ishida T, Inagaki A, et al. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer. 2007;120:2052-2057.
25. Kuwazaru Y, Hanada S, Furukawa T, et al. Expression of Pglycoprotein in adult T-cell leukemia cells. Blood. 1990;76: 2065-2071.
26. Ikeda K, Oka M, Yamada Y, et al. Adult T cell leukemia cells over-express the multidrug-resistance-protein (MRP) and lung resistance-protein (LRP) genes. Int J Cancer. 1999; 82:559-604.
27. Tagaya Y, Maeda Y, Mitsui A, et al. ATL-derived factor (ADF) an IL-2R/Tac inducer homologous to thioredoxin: possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J. 1989;8:757-767.
28. Sakashita K, Hattori T, Miller CW, et al. Mutations of the p53 gene in adult T-cell leukemia. Blood. 1992;79:477-480.
29. Gill P, Harrington W, Kaplan M, et al. Treatment of adult T-cell leukemia/lymphoma with a combination of interferon alpha and zidovudine. N Engl J Med. 1995;332:1744-1748.
30. Hermine O, Bouscary D, Gessain A, et al. Treatment of HTLV-1 associated adult T-cell leukemia-lymphoma with a combination of zidovudine and alpha-interferon. N Engl J Med. 1995;332:1749-1751.
31. Hermine O, Allard I, Levy V, et al. A prospective phase II clinical trial with the use of ziduvudine and alpha interferon in the acute and lymphomatous forms of adult T-cell leukemia/ lymphoma. Hematology J. 2002;3:276-282.
32. Matutes E, Taylor GP, Cavenagh J, et al. Interferon alpha and zidovudine therapy in adult T-cell leukemia lymphoma: response and outcome in 15 patients. Br J Hematol. 2001; 113:779-784.
33. White JD, Wharfe G, Stewart DM, et al. The combination of zidovudine and interferon alpha-2b in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma. 2001;40: 287-294.
34. Bazarbachi A, Panelatti G, Ramos JC, et al. A worldwide meta-analysis on the use of zidovudine and interferon-alpha for the treatment of adult T-cell leukemia/lymphoma. Abstract 2049. Presented at The American Society of Hematology 49th Annual Meeting, Atlanta, Georgia, December 8-11, 2007.
35. Ratner L. Adult T cell leukemia lymphoma. Front Biosci. 2004;9:2852-2859.
36. Hale G. The CD 52 antigen and development of CAMPATH antibodies. Cytotherapy. 2001;3:137-143.
37. Nagasaki A, Taira N, Tomoyose T, et al. [Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus - possible therapeutic effect of lamivudine combined with chemotherapy] [in Japanese]. Gan To Kagaku Ryoho. 2006;33:683-686.
38. Lymphoma Study Group. Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Leuk Res. 1991;15:81-90.
39. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
40. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004; 103:2474-2479.
41. Blumenstein BA. A comment on the utility of recursive partitioning. J Clin Oncol. 2005;23:4254-4255.
42. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453-459.